Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACHE | P22303 | 6/20 | 0.53 |
| ▸ | BCHE | P06276 | 2/20 | 0.50 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.50 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.48 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3524495 | 1.00 | ACHE (0.53) | ACHEBCHEOPRM1CHRM2CHRM3 | |
| SCHEMBL1995216 | 0.84 | OPRM1 (0.47) | ACHEBCHEOPRM1CHRM2CHRM3 | |
| SCHEMBL3548654 | 0.84 | OPRM1 (0.47) | ACHEBCHEOPRM1CHRM2CHRM3 | |
| SCHEMBL3548657 | 0.84 | OPRM1 (0.47) | ACHEBCHEOPRM1CHRM2CHRM3 | |
| SCHEMBL3548653 | 0.84 | OPRM1 (0.47) | ACHEBCHEOPRM1CHRM2CHRM3 | |
| SCHEMBL3625675 | 0.83 | CYP2D6 (0.49) | ACHEBCHE | |
| SCHEMBL3643830 | 0.81 | KCNH2 (0.49) | ACHEBCHE | |
| SCHEMBL8844605 | 0.80 | OPRM1 (0.50) | OPRM1CHRM2CHRM3 | |
| SCHEMBL3686563 | 0.80 | DRD4 (0.55) | — | |
| SCHEMBL3020210 | 0.80 | DRD4 (0.55) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2516420-B1 | AMINOALKYLPYRIMIDINE DERIVATIVES AS HISTAMINE H4 RECEPTOR ANTAGONISTS | MEDICIS PHARMACEUTICAL CORP (US) | 2018-08-22 | — | — | EP | disclosed |
| US-8901146-B2 | Aminoalkylpyrimidine derivatives as histamine H4 receptor antagonists | MEDICIS PHARMACEUTICAL CORPORATION (US) | 2014-12-02 | — | — | US | disclosed |
| US-20130018031-A1 | AMINOALKYLPYRIMIDINE DERIVATIVES AS HISTAMINE H4 RECEPTOR ANTAGONISTS | MEDICIS PHARMACEUTICAL CORPORATION (US) | 2013-01-17 | — | — | US | disclosed |
| US-20090306038-A1 | 2-Aminopyrimidine derivatives as modulators of the histamine H4 receptor activity | PALAU PHARMA, S.A. (ES) | 2009-12-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130018031-A1 | AMINOALKYLPYRIMIDINE DERIVATIVES AS HISTAMINE H4 RECEPTOR ANTAGONISTS | HRH4, HRH2, HRH3 | ACHE 2884/4885BCHE 997/4885OPRM1 254/4885 |
| US-20090306038-A1 | 2-Aminopyrimidine derivatives as modulators of the histamine H4 receptor activity | HRH4, HRH2, HRH3 | ACHE 2704/4885BCHE 1411/4885OPRM1 164/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.